A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-31

Study Completion Date

2021-04-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM). Approximately 20 subjects will be enrolled in Part A and approximately 30 subjects in Part B.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

NCT03590626

Non Alcoholic Fatty Liver Disease Type2 Diabetes Mellitus

COMPLETED NA

The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

NCT02765399

Type 2 Diabetes

COMPLETED PHASE4

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

NCT01509742

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE1

Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects

NCT02408705

Type 1 Diabetes Mellitus

COMPLETED PHASE2

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

NCT05407961

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 2-part exploratory Phase 2 study.

Part A is a randomised, double-blind, placebo-controlled study to evaluate the effect of MEDI0382 (also known as Cotadutide) administered once daily subcutaneously (SC) for 28 days on hepatic glycogen metabolism in overweight and obese subjects with T2DM. Part A is planned to randomise up to 20 subjects. Subjects from Part A will not be re-enrolled in Part B.

Part B is an exploratory Phase 2 randomised, double-blind, placebo-controlled and open-label active comparator study to evaluate the effect of MEDI0382 on hepatic glycogen metabolism in overweight and obese subjects with T2DM. Part B is planned to randomise approximately 30 subjects (not to exceed a maximum of 35 subjects). Subjects in Part B will be randomised to receive double-blind MEDI0382 or placebo, or open-label liraglutide once daily for 35 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MEDI0382 (Part A)

MEDI0382 administered subcutaneously (Part A)

Group Type EXPERIMENTAL

MEDI0382

Intervention Type DRUG

MEDI0382 administered subcutaneously

Placebo (Part A)

Placebo comparator administered subcutaneously (Part A)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo administered subcutaneously

Liraglutide (Part B)

Active comparator administered subcutaneously (Part B)

Group Type ACTIVE_COMPARATOR

Liraglutide

Intervention Type DRUG

Liraglutide administered subcutaneously

MEDI0382 (Part B)

MEDI0382 administered subcutaneously (Part B)

Group Type EXPERIMENTAL

MEDI0382

Intervention Type DRUG

MEDI0382 administered subcutaneously

Placebo (Part B)

Placebo comparator administered subcutaneously (Part B)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo administered subcutaneously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEDI0382

MEDI0382 administered subcutaneously

Intervention Type DRUG

Placebo

Placebo administered subcutaneously

Intervention Type DRUG

Liraglutide

Liraglutide administered subcutaneously

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index (BMI) ≥ 27 and ≤ 40 kg/m2 (inclusive) at screening
* Glycated haemoglobin (HbA1c) ≤ 8.0% at screening
* Diagnosed with T2DM with glucose control managed with metformin monotherapy where no significant dose change (increase or decrease ≥ 500 mg/day) has occurred in the 3 months prior to screening

Exclusion Criteria

* Any subject who has received another investigational product as part of a clinical study or a GLP-1 analogue-containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening
* Any subject who has received any of the following medications prior to the start of the study:

* Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion naltrexone, phentermine-topiramate, phentermine, lorcaserin)
* Opiates, domperidone, metoclopramide or other drugs known to alter gastric emptying
* Glucagon
* Warfarin
* Any contraindication to magnetic resonance imaging/MRS scanning including claustrophobia or dislike of confined spaces
* Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus (T1DM) or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening
* Recurrent unexplained hypoglycaemic episodes (defined as glucose \< 3.0 mmol/L or \< 54 mg/dL on more than 2 occasions in 6 months prior to screening)
* Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper GI tract (including weightreducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data
* Acute or chronic pancreatitis
* Significant hepatic disease (except for NASH or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening:

* Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)
* Alanine transaminase (ALT) ≥ 3 × ULN
* Total bilirubin ≥ 2 × ULN
* Impaired renal function defined as estimated glomerular filtration rate (eGFR) \< 30 mL/minute/1.73m2 at screening (glomerular filtration rate estimated according to Modification of Diet in Renal Disease (MDRD) using MDRD Study Equation IDMS-traceable (International System of Units \[SI\] units)
* Poorly controlled hypertension defined as:

* Systolic blood pressure (BP) \> 180 mm Hg
* Diastolic BP \> 105 mm Hg After 10 minutes of supine rest and confirmed by repeated measurement at screening.
* Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or subjects who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening
* Severe congestive heart failure (New York Heart Association Class III or IV)
* Basal calcitonin level \> 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia
* History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer
* Any positive results for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody
* Substance dependence or history of alcohol abuse and/or excess alcohol intake (defined as \> 21 units per week for a male subject, and \>14 units per week for a female subject). Subjects must have a negative alcohol test result at screening and prior to randomisation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No